ACHV - Achieve Life Sciences, Inc.
| Previous Close | 0.9600 |
| Open | 0.9553 |
| Bid | 0.0000 x 2900 |
| Ask | 0.0000 x 900 |
| Day's Range | 0.9100 - 0.9553 |
| 52 Week Range | 0.8300 - 4.6300 |
| Volume | 65,520 |
| Avg. Volume | 131,522 |
| Market Cap | 7.602M |
| Beta (3Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3450 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- Zacks Small Cap Research
ACHV: After Capital Raise Ready for Phase III
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Third Quarter 2019 Operational and Financial Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its third quarter results for 2019 and filed the companion 10-Q on November 6, 2019. An S-1 was simultaneously issued targeting a $10 million raise in order to partially fund the upcoming Phase III trials. Following the
- PR Newswire
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia , Nov. 6, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
CNW GroupAchieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
- Simply Wall St.
What Type Of Shareholder Owns Achieve Life Sciences, Inc.'s (NASDAQ:ACHV)?
Every investor in Achieve Life Sciences, Inc. (NASDAQ:ACHV) should be aware of the most powerful shareholder groups...
- PR Newswire
Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
"Successful Smoking Abstinence with Cytisinicline in the ORCA-1 Trial: What Happens Next?" will be presented at the SRNT-O meeting by Achieve's Chief Scientific Officer, Dr. Anthony Clarke, on Friday, October 25th in Sydney. The results of the ORCA-1 trial, to be discussed in the presentation, confirm that future Phase 3 clinical trials are expected to utilize 3.0 mg TID dosing of cytisinicline. The Company plans to extend dosing in the Phase 3 trials from 25 days to 42 days, or six weeks.
- PR Newswire
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their maximum tolerated dose (MTD) study. The results indicate a lack of dose-limiting toxicity as defined by protocol criteria even at the highest 30 mg single, oral dose of cytisinicline evaluated in the study. This study, initiated in March 2019, is required by the FDA as part of a New Drug Application (NDA) for marketing approval in the United States.
- Zacks Small Cap Research
ACHV: Post Phase II Investor Day
By John Vandermosten, CFA NASDAQ:ACHV Achieve Life Sciences, Inc. (NASDAQ:ACHV) held its first investor day following the read out of the ORCA-1 trial on September 20, 2019. The event was introduced by CFO John Bencich and included a roundtable discussion moderated by analysts Michael Higgins of Ladenburg Thalmann and Jason McCarthy of Maxim Group. The key opinion
- PR Newswire
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on Friday, September 13th in Oslo. Topline results, reported in June of 2019, have led to the selection of 3.0 mg, three times daily (TID) dosing for future Phase 3 development. The 3.0 mg TID treatment arm demonstrated a 54% abstinence rate at week 4, compared to 16% for placebo (p
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Achieve Life Sciences, Inc. (NASDAQ:ACHV)?
Anyone researching Achieve Life Sciences, Inc. (NASDAQ:ACHV) might want to consider the historical volatility of the...
- PR Newswire
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
The event will include an updated data presentation by the primary investigator of the Phase 2b ORCA-1 trial of cytisinicline. It will also feature a panel discussion moderated by leading healthcare analysts, Michael Higgins from Ladenburg Thalmann and Jason McCarthy from Maxim Group, with participation from four esteemed medical experts in the field of smoking cessation.
- PR Newswire
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia , Sept. 4, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- Zacks Small Cap Research
ACHV: SRNT Presentation Next on Agenda
Achieve Life Sciences, Inc. (ACHV) released its second quarter results for 2019 and filed the companion 10-Q on August 8, 2019. No revenues were reported for the development stage company and operational expenses totaled $3.7 million producing a net loss of ($0.50) per share. During the three month period, the company completed the ORCA-1 Phase IIb study, was granted a patent for a new formulation of cytisinicline and reported statistically significant improvement in quit rates for cytisinicline.
- CNW Group
/C O R R E C T I O N -- Achieve Life Sciences, Inc./
/C O R R E C T I O N -- Achieve Life Sciences, Inc./
- CNW Group
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
- PR Newswire
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, July 23, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced it has extended its strategic collaboration with the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH).
- Simply Wall St.
Did You Manage To Avoid Achieve Life Sciences's (NASDAQ:ACHV) Painful 55% Share Price Drop?
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...
